^
9h
Clinicopathological and molecular genetic alterations in monomorphic-epitheliotropic intestinal T-cell lymphoma of the small intestine. (PubMed, Eur J Med Res)
Our findings demonstrate that mutations in JAK3 and STAT5B of the JAK/STAT pathway and inactivation of the oncogene SETD2 markedly contribute to the lymphomagenesis of MEITL.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • BCOR (BCL6 Corepressor) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • JAK3 (Janus Kinase 3) • NCAM1 (Neural cell adhesion molecule 1) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • ITGAE (Integrin Subunit Alpha E) • SPN (Sialophorin)
|
TP53 mutation • CD8 expression • BCOR mutation • JAK3 mutation • SETD2 mutation
9h
Diverse B-cell tumors associated with t(14;19)(q32;q13)/IGH::BCL3 identified by G-banding and fluorescence in situ hybridization. (PubMed, J Clin Exp Hematop)
The 5 cases shared IGHV preferentially used in B-CLL cells, but the genes were unmutated in 2 B-CLL/SLL cases and significantly mutated in the remaining 3. B-cell tumors with t(14;19)(q32;q13) can be divided into B-CLL/SLL and DLBCL groups, and the anatomy of IGH::BCL3 in the latter may be different from that of the former.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL3 (BCL3 Transcription Coactivator)
|
MYC expression
9h
Extranodal natural killer/T-cell lymphoma coexisting with peripheral T-cell lymphoma, not otherwise specified. (PubMed, J Clin Exp Hematop)
However, ascites did not improve when treated with micafungin for Candida peritonitis. PTCL-NOS, chemotherapy, sepsis, and prednisone might have led to immunodeficiency and reactivation of EBV, which might be one of the pathophysiologies for developing ENKTL. Our case indicates that measuring EBV-DNA in the blood is a simple and prompt examination to detect complications of EBV-associated lymphoma.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule)
|
CD8 positive • CD4 positive
16h
Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients-Case Control Study. (PubMed, Med Sci (Basel))
Our study indicates that HLA-C*02:02 and HLA-C*12:02 are positively associated with chronic lymphoproliferative disorders for our Romanian patients while HLA-DRB1*11:01, HLA-DRB1*13:02, and HLA-B*35:02 alleles have a protective role against these diseases.
Journal
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
HLA-A*11
18h
Lymphomatoid Papulosis With T-cell Receptor-Gamma Delta Expression: A Clinicopathologic Case-series of 26 Patients of an Underrecognized Immunophenotypic Variant of Lymphomatoid Papulosis. (PubMed, Am J Surg Pathol)
Our case series, the largest international cohort of γδ T cell predominant LyP cases, confirms marked clinicopathologic heterogeneity that may contribute to misdiagnosis, reasserting the need to identify classic clinical features, CD30+ T-cell components, and markers of cytotoxicity when dealing with this differential diagnosis. A limitation of this study includes somewhat limited follow-up, histologic, and immunophenotypic information for some cases.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
22h
Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis. (PubMed, Int J Hematol)
Fourteen patients with known GVHD underwent transplantation between 50 and 365 days after their last dose of mogamulizumab, while 2 underwent transplantation within 50 days after treatment. Based on this limited evidence, GVHD was not associated with the time interval from last mogamulizumab dose to transplantation.
Retrospective data • Journal
|
CCR4 (C-C Motif Chemokine Receptor 4)
|
Poteligeo (mogamulizumab-kpkc)
2d
Gamma-delta T-cell acute lymphoblastic lymphoma/leukemia: a report of a rare entity. (PubMed, J Hematop)
Targeted DNA-based NGS detected a tier II oncogenic variant in NOTCH1 (c.7375C > T, p.Gln2459Ter) at a VAF of 21%. This case of γδ T-ALL highlights a rare entity and adds to the literature, albeit scant, which may aid in better recognition and classification.
Journal
|
NOTCH1 (Notch 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule)
3d
HBI-8000 improves heart failure with preserved ejection fraction via the TGF-β1/MAPK signalling pathway. (PubMed, J Cell Mol Med)
In conclusion, our data suggest that HBI-8000 inhibits fibrosis by modulating the TGF-β1/MAPK pathway thereby improving HFpEF. Therefore, HBI-8000 may become a new hope for the treatment of HFpEF patients.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
Epidaza (chidamide)
3d
STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma. (PubMed, Cell Rep Med)
The core autoregulatory transcriptional circuitry activity is reinforced by MYC binding to the enhancer regions associated with STAT3 and each of the core regulatory transcription factors. Thus, activation of STAT3 provides the crucial link between aberrant tyrosine kinase signaling and the core transcriptional machinery that drives tumorigenesis and creates therapeutic vulnerabilities in ALCL.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IKZF1 (IKAROS Family Zinc Finger 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IRF4 (Interferon regulatory factor 4) • BATF3 (Basic Leucine Zipper ATF-Like Transcription Factor 3)
|
ALK fusion • ALK mutation
4d
Clinicopathological features of adult T-cell leukemia/lymphoma with T-follicular helper phenotype. (PubMed, Cancer Med)
Some patients with ATLL may present a TFHP, which should not preclude the diagnosis of ATLL. Although presenting a TFHP does not affect prognosis, it is important to identify cases of ATLL with a TFHP since it may inform future treatment strategies.
Journal
|
FOXP3 (Forkhead Box P3) • CRP (C-reactive protein)
|
FOXP3 expression
4d
Characterization of primary small intestinal lymphoma: a retrospective study based on double balloon endoscopy. (PubMed, BMC Gastroenterol)
This study provides clinical characteristics of patients with PSIL. Thicker intestinal wall and aneurismal dilation detected on CT scan and deeper ulcer on DBE examination helps to establish a diagnosis of DLBCL.
Retrospective data • Journal
|
CRP (C-reactive protein)
|
LDH elevation
6d
EXALT-2: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (clinicaltrials.gov)
P=N/A, N=150, Recruiting, Medical University of Vienna | Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
Trial completion date • Trial primary completion date
|
FoundationOne® Heme CDx
7d
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma (clinicaltrials.gov)
P1, N=151, Active, not recruiting, Corvus Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
soquelitinib (CPI-818)
7d
Genomic profiling of Mycosis Fungoides identifies patients at high risk of disease progression. (PubMed, Blood Adv)
By analyzing the clonal heterogeneity and the clonal evolution of the cohort, we defined different phylogenetic pathways of the disease with acquisition of JUNB, gain10p15.1 (IL2RA and IL15RA), or del12p13.1 (CDKN1B) at progression. These results establish the genomics and clonality of MF and identify potential patients at risk of progression, independent of their clinical stage.
Journal
|
TET2 (Tet Methylcytosine Dioxygenase 2) • IL2RA (Interleukin 2 receptor, alpha) • TNFAIP3 (TNF Alpha Induced Protein 3) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)
|
TET2 mutation
7d
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) (clinicaltrials.gov)
P1, N=45, Active, not recruiting, CRISPR Therapeutics AG | Recruiting --> Active, not recruiting
Enrollment closed
|
CTX130
7d
Mapping Emotional Dynamics During Corticosteroid Treatment (clinicaltrials.gov)
P=N/A, N=12, Recruiting, Leiden University Medical Center | Trial completion date: Jun 2023 --> Mar 2025 | Trial primary completion date: Jun 2023 --> Mar 2025
Trial completion date • Trial primary completion date
9d
Cutaneous lymphoproliferative disorders: Back to the future. (PubMed, J Cutan Pathol)
While the 2022 ICC introduced the term "primary cutaneous marginal zone LPD," in the 5th edition of the WHO classification PCMZL is maintained. In this review we describe the background and rationale of the continually changing terminology of these conditions and discuss the clinical consequences of downgrading malignant lymphomas to LPDs.
Review • Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
9d
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=20, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • CD34 (CD34 molecule)
|
cytarabine • etoposide IV • etoposide oral • carmustine • melphalan • Simulect (basiliximab)
10d
Insulin-like Growth Factor II mRNA-binding Protein 3 is a Highly Sensitive Marker for Intravascular Large B-cell Lymphoma: Immunohistochemical Analysis of 152 Pathology Specimens From 88 Patients. (PubMed, Am J Surg Pathol)
However, of the 40 negative control samples, IMP3-positive non-germinal center B cells were detected in only 2 samples (P= 0.0131) and no intravascular IMP3-positive B cells suspicious for IVLBCL were identified. Altogether, IMP3 immunohistochemistry is a highly sensitive marker of IVLBCL and can be a helpful adjunct for IVLBCL diagnosis.
Journal
|
PAX5 (Paired Box 5) • IGF2 (Insulin-like growth factor 2)
10d
Journal
|
CD4 (CD4 Molecule)
|
CD4 expression
10d
Trial completion
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Opdivo (nivolumab) • cabiralizumab (BMS-986227)
10d
New P2 trial
|
Tyvyt (sintilimab) • oxaliplatin • Oncaspar liquid (pegaspargase)
12d
The RNA sequencing results revealed the expression of different genes and signaling pathways during chemotherapy resistance in peripheral T-cell lymphoma. (PubMed, BMC Med Genomics)
Our study revealed that the expression of specific genes, including TNFRSF1B, TRADD2, and MAP3K7, may play an important role in chemotherapy resistance in peripheral T-cell lymphoma. Moreover, we identified the downregulation of the TNF signaling pathway, a crucial pathway involved in cell survival, death, and differentiation, as a potential contributor to the development of chemotherapy resistance in peripheral T-cell lymphoma. These findings provide valuable insights into the molecular mechanisms underlying chemotherapy resistance and highlight potential targets for overcoming treatment resistance in this challenging disease.
Journal
|
MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7) • TNFRSF1B (TNF Receptor Superfamily Member 1B)
12d
Retrospective data • Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
12d
The relationship and clinical significance of serum cytokine expression level and skin pruritus in patients with Hodgkin lymphoma and angioimmunoblastic T-cell lymphoma. (PubMed, Int Immunopharmacol)
Differences in serum cytokine profiles between HL and AITL subgroups are also highlighted. These findings offer valuable insights for clinical intervention in managing lymphoma-related pruritus.
Journal
|
IL1B (Interleukin 1, beta)
13d
Journal
|
NCAM1 (Neural cell adhesion molecule 1)
|
NCAM1 expression
13d
Pigmented purpura dermatosis-like mycosis fungoides: four case reports and a review of published cases. (PubMed, Eur J Dermatol)
If persistent or generalized purpuric lesions are present, PPD-like MF should be taken into consideration. A thorough physical examination combined with pathological findings may lead to a correct diagnosis.
Review • Journal
|
CD4 (CD4 Molecule) • CD7 (CD7 Molecule)
13d
Oracle: Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL (clinicaltrials.gov)
P3, N=86, Active, not recruiting, The Lymphoma Academic Research Organisation | Trial completion date: Feb 2024 --> Jun 2024
Trial completion date
|
PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • MME (Membrane Metalloendopeptidase)
|
PD-1 expression
|
gemcitabine • bendamustine • Istodax (romidepsin) • Onureg (azacitidine oral)
13d
From the archives of MD Anderson Cancer Center: Monomorphic epitheliotropic intestinal T-cell lymphoma: A case with an unusual immunophenotype and discussion of differential diagnosis. (PubMed, Ann Diagn Pathol)
Retreatment led to another one-year interval of clinical remission, but at last follow up the patient has relapsed disease involving the ileum and colon. We also discuss the differential diagnosis of MEITL.
Review • Journal • IO biomarker
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CCND1 (Cyclin D1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • CD34 (CD34 molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • GZMB (Granzyme B) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • CD99 (CD99 Molecule) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
SETD2 mutation
14d
The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers. (PubMed, Cancer Chemother Pharmacol)
These hepatic impairment effects reduced between-subject variability by only 5%-8% for their respective parameter, with a large amount of remaining unexplained variability. With further validation, this model can be leveraged to assess the need for dose adjustments in this patient population.
PK/PD data • Journal • Metastases
|
UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
|
UGT1A1*1*1
|
Beleodaq (belinostat)
15d
Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma (clinicaltrials.gov)
P2, N=36, Not yet recruiting, Yale University | Initiation date: Jan 2024 --> Jun 2024
Trial initiation date
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Poteligeo (mogamulizumab-kpkc)
15d
CAR-37 T Cells In Hematologic Malignancies (clinicaltrials.gov)
P1, N=6, Completed, Marcela V. Maus, M.D.,Ph.D. | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024
Trial completion • Trial completion date
|
TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • CD37 (CD37 Molecule)
|
TP53 mutation • CD37 expression
16d
GI-hNeoT-01: Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T (clinicaltrials.gov)
P1, N=6, Recruiting, BGI, China | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P1 | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2025
Enrollment open • Phase classification • Trial completion date • Trial primary completion date
|
cyclophosphamide • fludarabine IV
16d
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Northwestern University | Trial completion date: Apr 2024 --> Dec 2026 | Trial primary completion date: Nov 2023 --> Dec 2026
Trial completion date • Trial primary completion date
16d
Journal • CAR T-Cell Therapy • IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3 mutation
16d
Trial completion date • Metastases
|
azacitidine • Zolinza (vorinostat)
17d
Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma. (PubMed, Signal Transduct Target Ther)
In conclusion, the chemo-free regimen pegaspargase plus sintilimab was effective and safe in newly diagnosed, advanced stage NKTCL. Dysregulated lipid profile and immunosuppressive signature contributed to treatment resistance, providing an alternative therapeutic approach dual targeting fatty acid metabolism and CTLA-4 in NKTCL.
Journal • Metastases
|
PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • APOA1 (Apolipoprotein A-I)
|
Tyvyt (sintilimab) • Oncaspar liquid (pegaspargase)
17d
The 504th case: Multiple lymph node enlargement, renal insufficiency, blindness, and white matter lesions of the brain (PubMed, Zhonghua Nei Ke Za Zhi)
This patient was diagnosed with angioimmunoblastic T-cell lymphoma 5 years ago and underwent multiple lines of anti-tumor therapy, including cytotoxic chemotherapy; epigenetic modifying drugs such as chidamide and azacitidine; the immunomodulator lenalidomide; and targeted therapy such as rituximab, a CD20-targeting antibody, and brentuximab vedotin, which targets CD30...Anti-tumor therapy was suspended and ganciclovir was used. The serum viral load decreased and organ functions were stabilized. The purpose of this report was to raise clinicians' awareness of opportunistic virus reactivation during anti-tumor treatment.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
Rituxan (rituximab) • lenalidomide • azacitidine • Adcetris (brentuximab vedotin) • Epidaza (chidamide)
18d
Centrosome amplification and aneuploidy driven by the HIV-1-induced Vpr•VprBP•Plk4 complex in CD4+ T cells. (PubMed, Nat Commun)
Furthermore, HIV-1 WT, but not its Vpr mutant, induces multiple centrosomes and aneuploidy in human primary CD4+ T cells. We propose that the Vpr•VprBP•Plk4 complex serves as a molecular link that connects HIV-1 infection to oncogenesis and that inhibiting the Vpr C-terminal motif may reduce the occurrence of HIV-1-associated cancers.
Journal
|
CD4 (CD4 Molecule) • PLK4 (Polo Like Kinase 4)
19d
P1 data • Journal • Combination therapy
|
IL15 (Interleukin 15)
|
Bavencio (avelumab)
20d
Febrile Ulceronecrotic Mucha-Habermann Disease Associated With Hemophagocytic Lymphohistiocytosis: A Case Report and Review of the Literature. (PubMed, Am J Dermatopathol)
Treatment with an eight-week course of etoposide and dexamethasone for HLH led to rapid clinical improvement. Although potentially fatal, FUMHD often exhibits favorable outcomes and may resolve without recurrence, as in our patient. FUMHD should be considered in the differential diagnosis for patients presenting with cutaneous CD8+ necrotizing angiocentric lymphoproliferative disease complicated by HLH.
Review • Journal
|
CD8 (cluster of differentiation 8) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule)
|
CD7 expression
|
etoposide IV
21d
Immunobiology and treatment of cutaneous T-cell lymphoma. (PubMed, Expert Rev Clin Immunol)
Recent advances in immunology have provided new insights into the biology of malignant T cells. This in turn has led to the development of new therapies that modulate the immune system to facilitate tumor clearance or target specific aspects of tumor biology.
Review • Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)